Table 3 Extracellular vesicle-derived RNA in DLBCL
From: Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
References | Method | EV purification (QC) | Sample | RNA | Level | Result |
|---|---|---|---|---|---|---|
Diagnosis | ||||||
Caivano et al. [172] | RT-qPCR serum | DC (AFM/TEM) | 5 DLBCL 18 controls | miR-155 | NS | No difference |
Provencio et al. [103] | RT-qPCR plasma | DC (ACHE activity) | 60 DLBCL/38 FL 68 controls | BCL6 mRNA PTEN mRNA | Up Down | Higher level in mixed population of DBLCL/FL Lower level in mixed population of DBLCL/FL |
Di et al. [96] | Micro-array/ RT-qPCR serum | ExoQuick (NTA/TEM/WB) | 99 DLBCL 94 controls | miR-379-5p, miR-135a-3p, miR-4476 miR-483-3p, miR- 451a | Up Down | 5-miRNA signature (higher level of miR-379-5p, miR-135a-3p, miR-4476; lower level of miR-483-3p, miR-451a) was associated with DLBCL |
Xiao et al. [95] | RT-qPCR serum | ExoQuick (DLS/TEM/WB) | 89 DLBCL 48 controls | miR-451a | Down | Lower level in DLBCL |
Zare et al. [173] | RT-qPCR plasma | Exo-spin (Zetasizer/TEM/DB/ WB) | 48 DLBCL 6 controls | miR-146a | NS | No difference |
Response to therapy | ||||||
Provencio et al. [103] | RT-qPCR plasma | DC (ACHE activity) | 16 DLBCL/15 FL 68 controls 60 DLBCL/38 FL 68 controls | BCL6 mRNA PTEN mRNA | Up Down | Higher level of BCL-6 in posttreatment samples compared to pretreatment samples was associated with NR in mixed population of DBLCL/FL. lower level of PTEN at time of diagnosis was associated with PD/R in DLBCL subgroup |
Feng et al. [102] | RNA seq/RT-qPCR/serum | ExoQuick (DLS/ TEM/WB) | 116 DLBCL | miR-99a-5p, miR-125b-5p miR-10a-5p, miR-10b-5p | Up NS | Higher level differentiates therapy resistant group (SD/PD) from sensitive group (CR/PR) after R-CHOP |
Zare et al. [173] | RT-qPCR plasma | Exo-spin (Zetasizer/TEM/DB/WB) | 48 DLBCL 6 controls | miR-146a | NS | No association with treatment response after R-CHOP |
Xiao et al. [95] | RT-qPCR serum | ExoQuick (DLS/TEM/WB) | 89 DLBCL 48 controls | miR-451a | Up | Higher level differentiates response group (PR/CR) from non-response group (SD/PD) after R-CHOP |
Zare et al. [101] | RT-qPCR plasma | Exo-spin (Zetasizer/TEM/WB) | 48 ABC DLBCL | miR-155 miR-let-7 g miR-let-7i | Up Down NS | Higher level of miR-155 in non-responsive (PD/SD) and relapsed patients compared to responsive patients (CR/PR) and patients receiving R-CHOP Lower level of miR-let-7 g in patients receiving R-CHOP compared to non-responsive (PD/SD) and relapsed patients |
Prognosis | ||||||
Provencio et al. [103] | RT-qPCR plasma | DC (ACHE activity) | 16 DLBCL/15 FL 68 controls 60 DLBCL/38 FL 68 controls | BCL-xL mRNA AKT, C-MYC, BCL-6 mRNA | Up Up | Higher posttreatment level of BCL-xL was associated with a higher death rate in mixed population of DBLCL/FL Pretreatment presence of AKT and C-MYC/BCL-6 was respectively associated with worse PFS and OS in a mixed population of DBLCL/FL patients, responsive to rituximab-based chemotherapy |
Feng et al. [102] | RNA seq/RT-qPCR/serum | ExoQuick (DLS/ TEM/WB) | 116 DLBCL | miR-99a-5p, miR-125b-5p | Up | Higher level is associated with worse PFS |